Posted On: 04/21/2014 10:15:22 PM
Post# of 273317
Galena Biopharma (GALE) 1.85 $GALE
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Galena Biopharma, Inc. to Contact Brower Piven Before the May 5, 2014 Lead Plaintiff Deadline (GALE)
GlobeNewswire - Mon Apr 21, 5:20PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena" or the "Company"
(Nasdaq:GALE) common stock during the period between November 6, 2013 and February 14, 2014, inclusive (the "Class Period" .
U.S. District Court Judge Nixes Banning of Zogenix's Painkiller in Massachusetts
ACCESSWIRE - Mon Apr 21, 9:42AM CDT
A U.S. District Court judge stopped Massachusetts from banning the sale of Zogenix Inc.'s (NASDAQ: ZGNX) prescription painkiller Zohydro, saying that the decision was based on the principle that federal law superseded the state's action.
Hagens Berman: Galena Biopharma Investigation Proceeds in Light of May 5, 2014 Lead Plaintiff Deadline in Securities Fraud Class Actions
PR Newswire - Wed Apr 16, 6:56PM CDT
Hagens Berman Sobol Shapiro LLP an investor-rights law firm with offices in San Francisco has intensified its investigation on behalf of Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company" in light of the May 5, 2014 deadline to file for lead plaintiff in the securities fraud cases against the company. Investors who purchased Galena stock between May 9, 2013 and March 17, 2014 (the "Class Period" can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or visiting http://hb-securities.com/investigations/Galena.
Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
Lieff Cabraser Reminds Galena Biopharma, Inc. Investors of Upcoming Deadline in Class Action Litigation - GALE
Business Wire - Fri Apr 11, 5:28PM CDT
Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the May 5, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or otherwise acquired the securities of Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq:GALE) between May 9, 2013 and March 17, 2014, inclusive (the "Class Period" .
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Galena Biopharma, Inc. and Certain Officers - GALE
PR Newswire - Fri Apr 11, 3:14PM CDT
Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company" (NASDAQ: GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
GALENA BIOPHARMA, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against GALENA BIOPHARMA, INC. and Its Board and a Lead Plaintiff Deadline of May 5, 2014 -- GALE
Business Wire - Thu Apr 10, 11:15AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq: GALE) securities between November 6, 2013 and February 14, 2014.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Galena Biopharma, Inc. to Contact Brower Piven Before the May 5, 2014 Lead Plaintiff Deadline
Business Wire - Wed Apr 09, 4:14PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq: GALE) common stock during the period between November 6, 2013 and February 14, 2014, inclusive (the "Class Period" .
Financial Results Schedules, Approvals, Appointments, Product Launches, and Stock Movements - Analyst Notes on Allergan, Accuray, Cerus, Galena Biopharma, and ZELTIQ Aesthetic
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Accuray Incorporated (NASDAQ: ARAY), Cerus Corporation (NASDAQ: CERS), Galena Biopharma, Inc. (NASDAQ: GALE), and ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Hagens Berman Notifies Investors of Extended Class Period and May 5, 2014 Lead Plaintiff Deadline in Galena Biopharma, Inc. Securities Fraud Class Actions
PR Newswire - Mon Apr 07, 4:23PM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the May 5, 2014 deadline to file for lead plaintiff in a securities fraud case against Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company" . The Class Period has been extended to cover investors who bought stock between May 9, 2013 and March 17, 2014 (the "Class Period" . Investors who purchased Galena securities during the Class Period may contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or visiting http://hb-securities.com/investigations/Galena.
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Galena Biopharma, Inc.
Business Wire - Thu Apr 03, 12:03PM CDT
Glancy Binkow & Goldberg LLP reminds investors of Galena Biopharma, Inc. ("Galena" or the "Company" (NASDAQ:GALE) that all purchasers of Galena securities between November 6, 2013 and February 14, 2014, inclusive (the "Class Period" , have until May 5, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Galena Biopharma to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 03, 6:05AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 13th Annual Needham Healthcare Conference. The presentation will take place on Tuesday, April 8, 2014 at 8:40 a.m. ET at the Westin Grand Central Hotel in New York, NY.
FDA Panel Grants Market Approval of MannKind Corp.'s Inhalable Insulin
ACCESSWIRE - Wed Apr 02, 8:49AM CDT
On Apr. 1, MannKind Corp. (NASDAQ:MNKD) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 13 to 1 to recommend that Afrezza, its inhalable insulin, be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes.
Morning Analysis on Top Gainers -- Research on Teva Pharmaceutical Industries, Capstone Turbine, Cigna, and Galena Biopharma
PR Newswire - Tue Apr 01, 8:29AM CDT
The US markets saw a positive sentiment on Monday, March 31, 2014, with the NASDAQ Composite closing at 4,198.99, up 1.04%, the Dow Jones Industrial Average ending the session at 16,457.66, up 0.82% and the S&P 500 edging 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Capstone Turbine Corp. (NASDAQ: CPST), Cigna Corp. (NYSE: CI) and Galena Biopharma Inc. (NASDAQ: GALE). Free technical research on TEVA, CPST, CI and GALE can be downloaded upon signing up at:
Hagens Berman Reminds Galena Biopharma, Inc. Investors of May 5, 2014, Lead Plaintiff Deadline and Continued Securities Fraud Investigation
Business Wire - Mon Mar 31, 12:37PM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the May 5, 2014, deadline to file for lead plaintiff in a securities fraud case against Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company" . Investors who bought Galena securities between Nov. 6, 2013, and Feb. 14, 2014 (the "Class Period" , can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or by visiting http://hb-securities.com/investigations/Galena.
Today's Dead Cat Bounce Stock: Galena Biopharma (GALE)
at The Street - Mon Mar 31, 8:49AM CDT
Trade-Ideas LLC identified Galena Biopharma (GALE) as a "dead cat bounce" (down big yesterday but up big today) candidate
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 29, 7:00AM CDT
Spring might have sprung this week, but plenty of investors aren't feeling warm and fuzzy. That's especially the case for shareholders of this week's three horrendous health0care stocks. One of these stocks disappointed the market by simply...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Galena Biopharma, Inc. of Class Action Lawsuit and Upcoming Deadline -- GALE
GlobeNewswire - Fri Mar 28, 1:11PM CDT
Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq:GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Galena Biopharma, Inc.
Business Wire - Fri Mar 28, 8:49AM CDT
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Galena Biopharma, Inc. ("GALE" or the "Company" and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Galena Biopharma, Inc. to Contact Brower Piven Before the May 5, 2014 Lead Plaintiff Deadline (GALE)
GlobeNewswire - Mon Apr 21, 5:20PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena" or the "Company"
(Nasdaq:GALE) common stock during the period between November 6, 2013 and February 14, 2014, inclusive (the "Class Period" . U.S. District Court Judge Nixes Banning of Zogenix's Painkiller in Massachusetts
ACCESSWIRE - Mon Apr 21, 9:42AM CDT
A U.S. District Court judge stopped Massachusetts from banning the sale of Zogenix Inc.'s (NASDAQ: ZGNX) prescription painkiller Zohydro, saying that the decision was based on the principle that federal law superseded the state's action.
Hagens Berman: Galena Biopharma Investigation Proceeds in Light of May 5, 2014 Lead Plaintiff Deadline in Securities Fraud Class Actions
PR Newswire - Wed Apr 16, 6:56PM CDT
Hagens Berman Sobol Shapiro LLP an investor-rights law firm with offices in San Francisco has intensified its investigation on behalf of Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company"
in light of the May 5, 2014 deadline to file for lead plaintiff in the securities fraud cases against the company. Investors who purchased Galena stock between May 9, 2013 and March 17, 2014 (the "Class Period" can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or visiting http://hb-securities.com/investigations/Galena. Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
Lieff Cabraser Reminds Galena Biopharma, Inc. Investors of Upcoming Deadline in Class Action Litigation - GALE
Business Wire - Fri Apr 11, 5:28PM CDT
Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the May 5, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or otherwise acquired the securities of Galena Biopharma, Inc. ("Galena" or the "Company"
(Nasdaq:GALE) between May 9, 2013 and March 17, 2014, inclusive (the "Class Period" . SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Galena Biopharma, Inc. and Certain Officers - GALE
PR Newswire - Fri Apr 11, 3:14PM CDT
Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company"
(NASDAQ: GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. GALENA BIOPHARMA, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against GALENA BIOPHARMA, INC. and Its Board and a Lead Plaintiff Deadline of May 5, 2014 -- GALE
Business Wire - Thu Apr 10, 11:15AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. ("Galena" or the "Company"
(Nasdaq: GALE) securities between November 6, 2013 and February 14, 2014. SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Galena Biopharma, Inc. to Contact Brower Piven Before the May 5, 2014 Lead Plaintiff Deadline
Business Wire - Wed Apr 09, 4:14PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena" or the "Company"
(Nasdaq: GALE) common stock during the period between November 6, 2013 and February 14, 2014, inclusive (the "Class Period" . Financial Results Schedules, Approvals, Appointments, Product Launches, and Stock Movements - Analyst Notes on Allergan, Accuray, Cerus, Galena Biopharma, and ZELTIQ Aesthetic
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Accuray Incorporated (NASDAQ: ARAY), Cerus Corporation (NASDAQ: CERS), Galena Biopharma, Inc. (NASDAQ: GALE), and ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Hagens Berman Notifies Investors of Extended Class Period and May 5, 2014 Lead Plaintiff Deadline in Galena Biopharma, Inc. Securities Fraud Class Actions
PR Newswire - Mon Apr 07, 4:23PM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the May 5, 2014 deadline to file for lead plaintiff in a securities fraud case against Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company"
. The Class Period has been extended to cover investors who bought stock between May 9, 2013 and March 17, 2014 (the "Class Period" . Investors who purchased Galena securities during the Class Period may contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or visiting http://hb-securities.com/investigations/Galena. INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Galena Biopharma, Inc.
Business Wire - Thu Apr 03, 12:03PM CDT
Glancy Binkow & Goldberg LLP reminds investors of Galena Biopharma, Inc. ("Galena" or the "Company"
(NASDAQ:GALE) that all purchasers of Galena securities between November 6, 2013 and February 14, 2014, inclusive (the "Class Period" , have until May 5, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. Galena Biopharma to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 03, 6:05AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 13th Annual Needham Healthcare Conference. The presentation will take place on Tuesday, April 8, 2014 at 8:40 a.m. ET at the Westin Grand Central Hotel in New York, NY.
FDA Panel Grants Market Approval of MannKind Corp.'s Inhalable Insulin
ACCESSWIRE - Wed Apr 02, 8:49AM CDT
On Apr. 1, MannKind Corp. (NASDAQ:MNKD) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 13 to 1 to recommend that Afrezza, its inhalable insulin, be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes.
Morning Analysis on Top Gainers -- Research on Teva Pharmaceutical Industries, Capstone Turbine, Cigna, and Galena Biopharma
PR Newswire - Tue Apr 01, 8:29AM CDT
The US markets saw a positive sentiment on Monday, March 31, 2014, with the NASDAQ Composite closing at 4,198.99, up 1.04%, the Dow Jones Industrial Average ending the session at 16,457.66, up 0.82% and the S&P 500 edging 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Capstone Turbine Corp. (NASDAQ: CPST), Cigna Corp. (NYSE: CI) and Galena Biopharma Inc. (NASDAQ: GALE). Free technical research on TEVA, CPST, CI and GALE can be downloaded upon signing up at:
Hagens Berman Reminds Galena Biopharma, Inc. Investors of May 5, 2014, Lead Plaintiff Deadline and Continued Securities Fraud Investigation
Business Wire - Mon Mar 31, 12:37PM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the May 5, 2014, deadline to file for lead plaintiff in a securities fraud case against Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company"
. Investors who bought Galena securities between Nov. 6, 2013, and Feb. 14, 2014 (the "Class Period" , can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or by visiting http://hb-securities.com/investigations/Galena. Today's Dead Cat Bounce Stock: Galena Biopharma (GALE)
at The Street - Mon Mar 31, 8:49AM CDT
Trade-Ideas LLC identified Galena Biopharma (GALE) as a "dead cat bounce" (down big yesterday but up big today) candidate
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 29, 7:00AM CDT
Spring might have sprung this week, but plenty of investors aren't feeling warm and fuzzy. That's especially the case for shareholders of this week's three horrendous health0care stocks. One of these stocks disappointed the market by simply...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Galena Biopharma, Inc. of Class Action Lawsuit and Upcoming Deadline -- GALE
GlobeNewswire - Fri Mar 28, 1:11PM CDT
Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company"
(Nasdaq:GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Galena Biopharma, Inc.
Business Wire - Fri Mar 28, 8:49AM CDT
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Galena Biopharma, Inc. ("GALE" or the "Company"
and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
(0)
(0)
